| ID | 10024 |
| Vaccine Name | Comirnaty |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | RNA based vaccine |
| Vaccine Status | Approved |
| Manufacturer | BioNTech SE, Pfizer Inc. |
| Year of Manufacturing | NA |
| Manufacturing Country | Germany |
| Age | 18 - 85 years |
| Dosage | NA |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | SARS-CoV-2 spike protein mRNA encapsulated in a lipid nanoparticle |
| Description | NA |
| Approving Organisation | US FDA |
| Collaborating Organisation | NA |
| Other Countries | USA, Argentina, Brazil, Germany, South Africa, Turkey |
| Trade Name | BNT162b2, COVID-19 mRNA vaccine, Tozinameran |
| PMID | 32328406 |
| Clinical Trial ID | NA |
| Reference Link | https://pubmed.ncbi.nlm.nih.gov/32328406/ |
| Additional Links | https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf
|